Subsidiary HDM1002 of East China Pharmaceutical (000963.SZ) has received approval from the US FDA for clinical trials of its drug.

The Zhongtong Financial APP reported that Huadong Medicine (000963.SZ) announced that on July 22, 2025, its wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (referred to as "Zhongmei Huadong") received a notification from the US Food and Drug Administration (FDA) that the clinical trial application for the HDM1002 tablet drug submitted by Zhongmei Huadong has been approved by the FDA.